(Q35057374)

6 August 2017

A preclinical and clinical study of lithium in low-grade neuroendocrine tumors (English)

1 reference

6 August 2017

Sam J Lubner

1

1 reference

6 August 2017

Muthusamy Kunnimalaiyaan

2

1 reference

6 August 2017

Kyle D Holen

3

1 reference

6 August 2017

Li Ning

4

1 reference

6 August 2017

Mary Ndiaye

5

1 reference

6 August 2017

Noelle K Loconte

6

1 reference

6 August 2017

Daniel L Mulkerin

7

1 reference

6 August 2017

William R Schelman

8

1 reference

6 August 2017

Herbert Chen

9

1 reference

6 August 2017

language of work or name

1 reference

10 March 2011

1 reference

6 August 2017

1 reference

6 August 2017

16

1 reference

6 August 2017

4

1 reference

6 August 2017

452-457

1 reference

Lithium inhibits carcinoid cell growth in vitro

6 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Activity of sunitinib in patients with advanced neuroendocrine tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3119207

25 October 2018

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors

1 reference

12 December 2020

Metastatic neuroendocrine hepatic tumors: resection improves survival

1 reference

12 December 2020

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

1 reference

12 December 2020

10.1634/THEONCOLOGIST.2010-0323

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference